USANA Health Sciences (USNA) Projected to Post Quarterly Earnings on Tuesday

USANA Health Sciences (NYSE:USNAGet Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Tuesday, July 22nd. Analysts expect the company to announce earnings of $0.54 per share and revenue of $225.20 million for the quarter. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS.

USANA Health Sciences (NYSE:USNAGet Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.70 by $0.03. The business had revenue of $249.54 million during the quarter, compared to analysts’ expectations of $243.08 million. USANA Health Sciences had a return on equity of 8.94% and a net margin of 3.98%. During the same period in the prior year, the firm posted $0.86 EPS. On average, analysts expect USANA Health Sciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

USANA Health Sciences Trading Down 1.5%

Shares of USNA stock opened at $32.51 on Tuesday. The company has a market cap of $605.35 million, a price-to-earnings ratio of 17.86, a price-to-earnings-growth ratio of 1.05 and a beta of 0.64. The stock has a 50 day simple moving average of $30.41 and a 200-day simple moving average of $30.28. USANA Health Sciences has a 12-month low of $23.10 and a 12-month high of $48.85.

Insiders Place Their Bets

In related news, CFO G Doug Iiekking sold 4,548 shares of the stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $29.61, for a total value of $134,666.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Walter Noot sold 6,291 shares of the stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $30.29, for a total transaction of $190,554.39. The disclosure for this sale can be found here. Insiders sold 12,013 shares of company stock worth $360,149 over the last ninety days. 0.63% of the stock is currently owned by company insiders.

Institutional Trading of USANA Health Sciences

An institutional investor recently bought a new position in USANA Health Sciences stock. Empowered Funds LLC acquired a new stake in USANA Health Sciences, Inc. (NYSE:USNAFree Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,483 shares of the company’s stock, valued at approximately $687,000. Empowered Funds LLC owned about 0.14% of USANA Health Sciences as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 54.25% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, May 22nd.

Check Out Our Latest Stock Analysis on USNA

USANA Health Sciences Company Profile

(Get Free Report)

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

Read More

Earnings History for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.